BRPI0517950A - uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele - Google Patents

uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele

Info

Publication number
BRPI0517950A
BRPI0517950A BRPI0517950-5A BRPI0517950A BRPI0517950A BR PI0517950 A BRPI0517950 A BR PI0517950A BR PI0517950 A BRPI0517950 A BR PI0517950A BR PI0517950 A BRPI0517950 A BR PI0517950A
Authority
BR
Brazil
Prior art keywords
acquiring
loss
androgens
likelihood
reduce
Prior art date
Application number
BRPI0517950-5A
Other languages
English (en)
Inventor
Mohamed El-Alfy
Fernand Labrie
Lamia Azzi
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of BRPI0517950A publication Critical patent/BRPI0517950A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

USO DE ANDRóGENOS PARA REDUZIR A PROBABILIDADE DE ADQUIRIR OU PARA O TRATAMENTO DO ENVELHECIMENTO DA PELE. São revelados métodos inéditos de tratamento ou redução da probabilidade de adquirir doenças cutâneas causadas por deficiência de androgênio relacionada à idade, particularmente atrofia cutânea, perda de colágeno, perda de fibras elásticas, perda de tecido conjuntivo, celulite, e formação de rugas, em animais de sangue quente suscetíveis, incluindo seres humanos, que envolvem a administração de um androgênio e/ou um precursor esteróide sexual. Também são reveladas composições farmacêuticas para liberação do(s) ingrediente(s) ativo(s) úteis para a invenção.
BRPI0517950-5A 2004-11-01 2005-10-31 uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele BRPI0517950A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62411204P 2004-11-01 2004-11-01
PCT/CA2005/001652 WO2006047859A1 (en) 2004-11-01 2005-10-31 Use of androgens to reduce the likelihood of acquiring or to treat skin aging

Publications (1)

Publication Number Publication Date
BRPI0517950A true BRPI0517950A (pt) 2008-10-21

Family

ID=36318842

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517950-5A BRPI0517950A (pt) 2004-11-01 2005-10-31 uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele

Country Status (20)

Country Link
US (1) US20060178352A1 (pt)
EP (1) EP1807062A4 (pt)
JP (1) JP2008517952A (pt)
KR (1) KR20070073964A (pt)
CN (1) CN101094676A (pt)
AP (1) AP2007003982A0 (pt)
AU (1) AU2005301035A1 (pt)
BR (1) BRPI0517950A (pt)
CA (1) CA2585666A1 (pt)
EA (1) EA200700983A1 (pt)
GE (1) GEP20094833B (pt)
HR (1) HRP20070183A2 (pt)
IL (1) IL182844A0 (pt)
MA (1) MA29220B1 (pt)
MX (1) MX2007005098A (pt)
NO (1) NO20072642L (pt)
RS (1) RS20070185A (pt)
TN (1) TNSN07163A1 (pt)
WO (1) WO2006047859A1 (pt)
ZA (1) ZA200703531B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US8269380B2 (en) 2006-06-01 2012-09-18 Panasonic Corporation Brushless motor for washing machine having stress reduction on sensor casing and washing machine having the brushless motor mounted therein
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
WO2015055179A1 (de) * 2013-10-15 2015-04-23 Chelac Holding Gmbh Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
CN107949389A (zh) * 2015-09-30 2018-04-20 富士胶片株式会社 经皮吸收用组合物
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531437A (pt) * 1953-08-26
PT1382340E (pt) * 1993-01-19 2006-07-31 Endorech Inc Utilizacoes terapeuticas de desidroepiandrosterona para tratar libido diminuida e osteoporose
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
NZ536787A (en) * 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy

Also Published As

Publication number Publication date
CN101094676A (zh) 2007-12-26
WO2006047859A1 (en) 2006-05-11
EP1807062A1 (en) 2007-07-18
AU2005301035A1 (en) 2006-05-11
EA200700983A1 (ru) 2008-04-28
KR20070073964A (ko) 2007-07-10
JP2008517952A (ja) 2008-05-29
MX2007005098A (es) 2008-01-16
RS20070185A (sr) 2008-09-29
HRP20070183A2 (en) 2007-08-31
AP2007003982A0 (en) 2007-06-30
TNSN07163A1 (en) 2008-11-21
IL182844A0 (en) 2007-09-20
GEP20094833B (en) 2009-11-25
NO20072642L (no) 2007-07-30
MA29220B1 (fr) 2008-02-01
CA2585666A1 (en) 2006-05-11
EP1807062A4 (en) 2009-06-03
US20060178352A1 (en) 2006-08-10
ZA200703531B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
CY1125968T1 (el) Συσκευη και συστημα υποβοηθησης της καρδιας
WO2007089454A3 (en) Methods for enhancing skin treatments
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BRPI0013010B8 (pt) formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BRPI0507279A (pt) método e dispositivo para o tratamento do canal da teta de um animal
BR0212898A (pt) Método de tratamento de infecções do ouvido médio
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
TNSN07163A1 (en) Use of androgens to reduce the likelihood of acquiring or to treat skin aging
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
WO2003011327A3 (en) Secretin for the treatment of asthma
BRPI0415756A (pt) lipólise medicamentosa local, dirigida
DK1677806T3 (da) Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
NO20071238L (no) Fremgangsmater for leging av skader ved human IL-18 administrering
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
MX2012000503A (es) Metodo quimico para esterilizacion sexual y eliminacion de libido en mamiferos machos.
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.